Open access peer-reviewed chapter

New Strategy Treating Hepatitis B Virus (HBV) Infection: A Review of HBV Infection Biology

Written By

Yong-Yuan Zhang

Submitted: 25 April 2016 Reviewed: 29 September 2016 Published: 08 March 2017

DOI: 10.5772/66083

From the Edited Volume

Advances in Treatment of Hepatitis C and B

Edited by Naglaa Allam

Chapter metrics overview

1,920 Chapter Downloads

View Full Metrics


Chronic hepatitis B virus (HBV) infection affects 240 million people worldwide and represents a significant burden on public health. Current antiviral treatment of chronic hepatitis B mainly focuses on inhibiting viral replication. A main deficiency of the current treatment is unable to protect uninfected liver cells or hepatocytes that cleared HBV from next rounds of infection. HBV infection biology shows that natural clearance of HBV cccDNA from infected cells frequently occurs, HBV infection including chronic HBV infection is established and maintained by multiround infection, and the course of HBV infection is largely determined by the number of round of infection. Thus, an effective treatment of HBV infection must block new rounds of infection. A proposed new strategy for treating chronic HBV infection aims to immediately interrupt infection course and to achieve HbsAg seroconversion as early as possible. Under this strategy, a main target of antiviral treatment is extracellular viruses, and an effective therapeutics is specific neutralizing (anti-HBs) antibodies. A difference in tempo and efficiency of treating HBV infection between current antivirals and neutralizing antibody is that the antivirals inhibit viral infection only after cells are virus infected while the neutralizing antibody clears viruses before the infection of cells takes place.


  • hepatitis B virus
  • acute hepatitis B
  • chronic HBV infection
  • HBV infection biology
  • antivirals
  • neutralizing antibody
  • anti-HBs

1. Introduction: why we need a better understanding of HBV infection biology?

Chronic hepatitis B virus (HBV) infection affects 240 million people worldwide [1]. Estimated 4.5 million of new HBV infection occurs each year [2]. A significant portion of new HBV infections occurs in infants borne to HBV-positive mothers despite a fully scheduled HBV immunization. More than 90% of HBV-infected infants will become chronic [35], resulting in constant expansion of chronic HBV-infected population.

Chronic HBV infection can induce severe or repeated liver injury, which can lead to advanced liver diseases including cirrhosis [6, 7] and hepatocellular carcinoma [8]. The disease burden of HBV infection is enormous, and WHO reports that 780,000 people die of HBV-related liver diseases or complications annually [9]. In addition, as many as 70% of chronic HBV-infected patients who have persistently normal ALT already experienced significant alterations in liver histology [1013]. We need to provide more effective treatment to chronic HBV-infected patients.

Current antiviral treatment is recommended for chronic HBV-infected patients who have evidence of liver injury related to HBV infection [14, 15]. Antivirals that mainly consist of nucleos/tide analogues can potently inhibit HBV replication, mitigate liver injury and slowdown progression of necroinflammation in the liver [16, 17]. However, the current treatment rarely clears chronic HBV infection. Majority of chronic HBV-infected patients are not suitable for current antiviral treatment. Untreated patients, despite normal ALT history, can experience unpredictable flare-ups of liver injury [18, 19]. Exacerbation insults, if occurred in patients with chronic liver injury or significant alterations in liver histology despite normal ALT, can trigger acute chronic liver failure with up to 70% mortality [20, 21].

Clearly, the current antiviral treatment strategy and available antivirals do not meet clinical needs.

Here, we briefly discuss a number of limitations of current antiviral strategy and antivirals.

1.1. Current treatment strategy does not protect virus-cleared cells or uninfected cells from new rounds of infection

Current antiviral therapy is guided by belief and strategy that a viral infection can be cleared by directly inhibiting viral replication. This approach certainly mitigates viral diseases associated with viral replication, even clears viral infection under certain circumstances, for instance, a significant portion of chronic HCV infection can be cleared with a relatively short course of direct-acting antiviral agents [22, 23]. However, it does not take consideration of viral infection biology, which is featured with multiround infection (see below). This is why current antiviral strategy cannot clear chronic HBV infection. The NA-based antiviral therapy for chronic HBV infection, even with early generation of NAs like lamivudine, can clear HBV from HBV-infected cells, evidence includes wild-type (WT) virus, or early viral population was eliminated and replaced with drug-related mutant (MT) virus [24, 25]. Additional evidence consists of 5–6 logs reduction of serum HBV DNA level [26, 2729] and 100-fold reduction of intracellular total HBV DNA and cccDNA levels in treated animals and patients [3032]. However, during the same period, serum HBsAg level is only reduced by two- to three fold [33], suggesting HBsAg level remains constantly high. The enduring high level of HBsAg keeps depleting the limited amount of endogenous neutralizing antibodies and leaves HBV virions that are produced by infected cells in the same livers, unneutralized and infectious, which continue to cause new rounds of infection. Under the current antiviral strategy, virus-cleared cells can immediately become infected again, gains in clearing viral infection are continuously reversed, and it is extremely difficult to establish permanent and complete viral clearance under current antiviral strategy because virus-cleared cells and uninfected cells are not protected.

1.2. Antivirals target viral replication in infected cells and do not directly act against extracellular viruses

Two events occur simultaneously during antiviral therapy. One is viral replication is inhibited intracellularly, and the other is new rounds of infection continue as long as there are unneutralized extracellular viruses and susceptible cells that are not protected. Antivirals only suppress viral replication in infected cells, reducing production of new viruses that will lower level of extracellular viruses, which eventually lead to reducing new rounds of infection. Once no more viruses available for new rounds of infection, the infection course is actually interrupted, which brings the infection course to the end. Thus, the direct impact of treatment with antivirals is to reduce viral replication while an indirect impact is leading to limiting spread of infection, which really matters in containing and clearing viral infection. However, the antivirals do not directly act against extracellular viruses that may continuously cause new rounds of infection and compromise antiviral efficacy. This feature determines relatively ineffectiveness of direct antivirals in treating chronic HBV infection.

1.3. Effectiveness of antivirals depends on HBV replication efficiency

The third issue is that antivirals do not inhibit or kill viruses that were already produced. They only inhibit producing new viruses upon replication. Antivirals will not function if there was no active viral replication. Actual effectiveness of an antiviral in treating hepatitis B is largely determined by HBV replication efficiency. In clinic, a link between HBV replication level and antiviral response has been indicated. For instance, in patients with long-term entecavir therapy, a full virological response rate was 59, 84, 90, 93, and 95% after 48, 96, 144, 192, and 240 weeks of therapy, respectively [27]. Clearly, 59% of treated patients achieved the full virological response to entecavir in the first 48 weeks, but only 16, 6, 3 and 2% of net increased response were, respectively, achieved when the therapy was extended from 48 to 96, 144, 192 and 240 weeks. The net increased response rate was progressively declined along with extending therapy period since the viral replication was increasingly depressed to very low level. The replication-dependent effectiveness determines the direct antivirals are not effective against HBV infection with inactive replication, for instance in anti-HBe–positive patients with low HBV DNA level or only HBsAg positive patients.

1.4. Ineffective against severe acute HBV diseases

Direct antivirals would not be effective in treating severe acute hepatitis B since they take a few days or longer to significantly reduce viral replication or serum viral load (a log or greater) [3437]. They would take much longer time to mitigate pathologic injury and to improve clinical manifestations [38]. Relatively slow action and no direct inhibition of extracellular viruses highlight potential ineffectiveness of antivirals in treating fulminant hepatitis B and acute severe exacerbation of chronic HBV infection-induced liver injury, both of which induce rapidly deteriorated clinic course and high mortality [3941].

1.5. Antivirals alone cannot completely clear viral infection

Antivirals may be no longer effective once the viral replication was inhibited to low level. Residual viruses can be secreted out, or released by turnovers of infected cells, leading to clearing infection or infected cells. The released residual viruses are small in quantity and can be completely neutralized if there is relatively sufficient amount of endogenous neutralizing antibodies, which lead to stopping the course of viral infection by blocking new rounds of infection. This scenario likely happens to clearing chronic hepatitis C virus infection with direct antivirals.

The released residual viruses following potent inhibition of virus production will still be capable of causing new rounds of infection if there were no sufficient neutralizing antibodies, prolonging the course of chronic infection. This scenario likely happens to antivirals-treated HBV-infected patients.

Clearly, antivirals alone cannot complete clearing viral infection,which requires the presence of sufficient neutralizing antibodies.

What we need is new treatment strategies and new therapeutics that can improve current treatment approach and antivirals in treating chronic HBV infection.

We believe we can find effective solutions to current problems in treating chronic HBV infection through a better understanding of HBV infection biology, which will also accelerate developing new prophylactics and therapeutics.


2. Understanding HBV infection biology

2.1. Natural course of HBV infection

Infection biology is science illustrating fundamentals of infection, which is centered on understanding how a productive infection is established and maintained. Understanding of infection biology starts with understanding natural course of infection. In this review, we only focus on the natural course of HBV infection that causes hepatitis. The natural course of hepatitis B consists of initial infection, incubation period and clinical phase (Figure 1).

Figure 1.

Schematic illustration of a typical course of infection that consists of initial infection, incubation and clinical phases. Progression of infection course is directly driven by new rounds of infections. It also suggests the infection course can be ended at any stage as long as extracellular pathogens are completely neutralized.

2.1.1. Initial HBV infection

Initial infection represents beginning of an infection and it provides seed of infection and usually consists of a few or small clusters of infected cells in the liver. The initial infection is important, but it cannot become a full-blown infection without incubation period.

2.1.2. Incubation period

The incubation refers to a period between initial infection and appearance of clinical symptoms. Length of the incubation varies considerably from individual to individual, but it is required for every HBV infection that causes hepatitis, which suggests the number of virus involved in the initial infection is so small that cannot immediately cause significant injury or clinical manifestations. Likely sequential events during the incubation include that infected HBV replicates in initial infected cells, progeny viruses are released through secretion or/and cytopathic destruction of infected cells, resulting in new rounds of infection of more cells, most likely in neighboring areas because short distances between viruses and susceptible cells favor higher efficiency of infection. Continuously released viruses keep initiating new rounds of infections, infecting more cells and extending the scope of infection. When the number of destructed cells reached an extent that causes clinical symptoms, the incubation is progressing to clinical phase.

Requirement of incubation period in full-blown HBV infection provides evidence that more than one round infection is required to establish and maintain a full-blown infection or hepatitis B (Figure 1). Thus, acute hepatitis B is caused by multiround of infection.

A main factor that allows multiround of infection is that there is no sufficient amount of endogenous neutralizing antibodies to neutralize the released viruses.

New rounds of infections inevitably occur during the infection course as long as there are unneutralized extracellular viruses and susceptible cells.

2.1.3. Clinical phase of acute HBV infection

Acute HBV infection in adults is a self-limiting disease, and 95% of them will be recovered without treatment [42]. A unique kinetics of serum HBV DNA level during acute HBV infection includes a rapid fall of HBV DNA level after the peak (Figure 2), suggesting HBV infection is being progressively cleared from the liver, as evidenced by rising ALT level (a result of destructing the infected cells) at the same time frame. Critically, it also suggests no new rounds of HBV infection, implying a block of new rounds of infection is required for clearing HBV infection. A mechanism behind these changes is called “HBsAg seroconversion,” a hallmark for resolving HBV infection.

Figure 2.

Kinetics of serum HBV DNA and ALT levels during acute hepatitis B. HBV DNA quickly falls after the peak, which coincides with rising ALT level. The rapid fall of HBV DNA suggests no new round infection.

When destruction of the infected cells is started during acute HBV infection, it will initially cause transit elevation of serum HBsAg and HBV DNA levels by releasing viral particles. However, the serum HBsAg and HBV DNA levels will then keep falling because the number of infected cells that supply and replenish serum HBsAg and HBV virion is progressively reduced by the liver injury (the supply reduced) while the removal or the half-life of viral particles from/in circulation should be at a constant rate, contributing to rapidly significant reduction of serum HBsAg and HBV levels. At certain point, the relative ratio between amounts of HBV particles (both viral and subviral particles) and anti-HBs antibodies will be reversed from the former greatly exceeding the latter, to the latter exceeding the former (HBsAg seroconversion). This conversion creates a sufficient anti-HBs capacity to clear serum HBsAg and to block new round infection, which allows uninfected cells and cells that cleared HBV infection permanently stay infection free. This process highlights an indispensable requirement of anti-HBs antibodies in blocking new rounds of HBV infection and resolving HBV infection.

Different impacts of liver injury on outcomes of infection are expected if occurred at different frequencies. For instance, continuous or progressive liver injury at moderate or medium scale, as is in acute hepatitis B, or at massive scale as is in fulminant hepatitis can lead to complete clearance of HBV infection because of successful reversal of the ratio of serum HBsAg and anti-HBs. On the other hand, if occurred intermittently, it unlikely leads to a complete viral clearance as is in chronic hepatitis B because of no reversal of the ratio of HBsAg and anti-HBs. The different outcomes once again emphasize that HBsAg seroconversion is critically required for completely clearing HBV infection.

A HBV infection can be ended at any stage if subsequently released viruses were completely neutralized by endogenous neutralizing antibodies. Most of HBV infections are aborted during the incubation period without developing into a full-blown infection because relative amount of infected viruses is still low. Those individuals who ended the HBV infection before clinical stage only show detectable anti-HBs and anti-HBc antibodies without clinical manifestations and noticeable HBV infection history [43, 44].

Thus, a natural strategy to clear viral infection or end infection course utilized by the host is to include producing neutralizing antibodies to block new rounds of infection with newly released viruses [45]. However, in minority cases, the infection will advance to clinical stage or viral disease will be aggravated or clinical stage will be prolonged if the amount of endogenous neutralizing antibodies produced in the host is not high enough to neutralize all specific viruses during the incubation or clinical stage of infection. This is how acute and chronic infections are established.

Cellular immunity consists of two major functional mechanisms in controlling viral infection [4648], one is to kill infected cells by cytotoxic T cells that not only contribute to pathological changes of viral disease, but also release viruses for new rounds of infection if not neutralized. The impacts of killing infected cells by the specific immunity are similar to cytopathic effects of viruses. The other is to inhibit replication of viruses in the infected cells by cytokines, which will reduce the number of released viruses. From controlling infection point of view, the cellular immunity can be counterproductive or helpful dependent on net effect of two actions (the amount of virions released) as well as the level of specific neutralizing antibodies. A difference in tempo of clearing viral infection between cellular and humoral immunity is that the cellular immunity clears viral infection only after cells are virus infected while the neutralizing antibody clears viruses before the infection takes place, one step ahead of the cellular immunity (Figure 3). Humoral immunity of neutralizing antibody is direct, decisively effective and required for controlling viral infection. Once new rounds of infection were completely blocked by sufficient amount of neutralizing antibodies, the viral infection in the already infected cells will be cleared by virus secretion, cytopathic effects of viral replication, cell turnover or the cellular immunity. Alternatively, the viral infection will be restricted to those already infected cells if the infected cells were long-lived, implying that viral infection has been brought under control with the neutralizing antibody.

Figure 3.

Differences in tempo and efficiency of clearing viral infection between neutralizing antibody and antivirals. (A) Administrated neutralizing antibody immediately neutralizes extracellular viruses and protect uninfected cells; (B) administrated small molecule inhibitor first allows virus to infect cells then starts inhibiting viral replication in infected cells. It cannot immediately and completely remove viremia.

A chronic HBV infection is usually maintained by new rounds of infection. The chronic infection can be spontaneously cleared if the level of endogenous neutralizing antibodies is high and can neutralize all released viruses to stop new rounds of infection. For instance, spontaneous clearance of chronic HBV infection occurs at annual rates of 1–2% and is featured with seroconversion of HBsAg to anti-HBs antibody [49, 50].

2.1.4. A main risk that will prolong HBV infection course is extracellular viruses, and a main target in treating viral diseases is extracellular viruses

Clearly, to cure HBV infection, it is essential and also efficient to interrupt infection course that consists of repeated rounds of infection.

There are three consequent scenarios during the course of hepatitis B: one is the infected cells become lost, resulting in releasing more virions as a consequence of cytopathic effects of infected HBV, cell turnover or destruction by cellular immunity; the second one is the infection is spontaneously cleared from infected cells by virus secretion or/and cellular immunity that reduces production and release of viruses, a same outcome as inhibiting viral replication by antivirals, and the third one is the infected cells are relatively long-lived (non-cytopathic infection) and producing and releasing low or high level of viruses. A shared main consequence produced by each scenario is releasing viruses. Thus, a main target in treating HBV infection should be the extracellular viruses, which cause new rounds of infection. Direct antivirals like NAs are not agents that can directly counter the extracellular viruses. Overall effectiveness of treating chronic HBV infection will be significantly improved if neutralizing antibodies are employed.

2.2. HBV infection course and persistence

HBV infection is known for long incubation period that may last up to 6 months (average 2–3 months) [51, 52] before occurrence of clinical symptoms of acute HBV infection. We believed that multiround infection occurs during the incubation period. Duck hepatitis B virus (DHBV) experimental infection was utilized to verify this understanding of HBV infection dynamics during the incubation period. Ducklings were inoculated with high DHBV inoculation dose, and three animals were daily sacrificed for 7 days after inoculation. Viral core protein was stained on liver sections, and DHBV DNA was detected in liver tissues [45]. As shown in Figure 4A and B, DHBV infection rapidly expanded from a few clusters of initially infected cells in the infected livers and reached a full-blown infection in 7 days, showing there were repeatedly new rounds of infection that expanded the infection scope in the livers, even under the circumstances of experimental infection that used a very large inoculum.

Figure 4.

Multiround infection during the incubation period of DHBV infection. Viral replicative intermediates (A) and antigen-staining cells (B) were detected in livers of DHBV-infected ducks. Three ducks were sacrificed at the indicated days postinfection, and replicative intermediates were extracted from the liver. The viral DNA was detected by hybridization. The percent antigen-staining hepatocytes in some of the samples is indicated at the top of the lanes.

Are there continuously new rounds of infections after the full-blown HBV infection was established?

Current theory views that chronic HBV infection is a consequence of the host’s insufficient T-cell immunity that cannot kill all HBV-infected cells or cannot clear HBV infection from infected cells [53, 54], implying chronic HBV infection is a simple extension of the initial or early HBV infection; the hepatocytes, once infected with HBV, are long-lived and constantly infected with the same initial viruses during chronic course.

However, such view is not supported by experimental and clinical evidence.

Figure 5.

Repeated new rounds of infection after a liver was fully infected. Three-day-old ducklings (n = 20) were infected with an inoculum containing both DHBV3 and 16. Six biopsies were performed on one animal at day 11, 32, 66, 88, 109 and 131 days postinfection (shown in this figure). cccDNA genotypes were determined by sequencing PCR products amplified from cccDNA released from single individual nuclei. DHBV3-infected cells were expanding, while DHBV16-infected cells were decreasing during the period of six times of biopsies, suggesting ongoing viral clearance and new rounds of infection. As a quality control for our procedure, the same number of nuclei isolated from DHBV3 and DHBV16 singly infected livers was mixed and single individual nucleus was sorted into individual well of 96-well plates for PCR amplification and sequencing. No dual infections were detected in 128 mixed nuclei, suggesting that our procedure for detection is valid.

To investigate whether DHBV infection and DHBV-infected cell populations are stable after liver was fully infected, 3-day-old ducklings were inoculated with a large inoculum containing both DHBV 3 and 16 viruses at 1:1 ratio. The first biopsy was conducted at day 11 by which the liver was fully infected, and then, series of liver biopsies were performed every 3 weeks. Distinct genetic markers in two viral genomes allowed us to monitor kinetic changes in DHBV 3 and 16 singly and dually infected populations by determining cccDNA genotypes at single nucleus level. It was found that majority of hepatocytes were singly infected and nearly 20% of cells exhibited dual infection with both viruses at day 11 postinfection (p.i.) (Figure 5). We detected new rounds of infections at each of 5 time points after day 11 because the fraction of DHBV3-infected cells was expanding, but the expansion occurred in only singly infected fashion, suggesting that already infected cells resisted superinfection while the new rounds of infection were occurring. It also suggested occurrence of viral clearance in DHBV-infected liver, which generated uninfected cells for new rounds of infection. This viral clearance conclusion is consistent with data showing that the fraction of DHBV16-infected cells was decreased from 80% at day 32, to about 40% at day 131 p.i., and at least 40% of DHBV16-infected cells either cleared the infection or were eliminated, which triggered regeneration of hepatocytes. Either of two scenarios would produce uninfected cells targeted by new rounds of infection. The results suggest DHBV infection even after the full infection was established in the liver remains dynamic and is featured with new rounds of infections.

The results on clearing of DHBV16 cccDNA and new establishing of DHBV3 cccDNA pool from new rounds of infection are consistent with the early reports, in which a replication defective pre-core mutant or revertants successfully spread infection and became the predominant viral population following elimination of wild type (WT) or the initially inoculated viruses (Figure 6) [55, 56]. Taken together, all results suggest that a chronic DHBV infection is not a simple extension of the initial infection because the initial infection was cleared and the early cccDNA genotypes were replaced. Rather chronic DHBV infection course is dynamic and consists of viral clearance and new rounds of infection. Thus, repeatedly new rounds of infection maintain the persistence of viral cccDNA and prolong the course of chronic infection.

Figure 6.

WT DHBV was being replaced over time. The fraction of WT DHBV DNA in serum of four DHBV-infected ducks was determined by PCR sequencing assay and plotted against the time postinfection. The kinetics of replacing WT DHBV infection suggests DHBV infection in fully infected livers remains dynamic and featured with clearing WT and new rounds of infection with MT.

These conclusions are supported by clinical HBV infection data.

It is well known that WT HBV infection is frequently replaced with mutant (MT) infection [25, 5782] in untreated chronic HBV-infected patients. For instance, naturally occurring pre-core, core, pre-S and S mutants became only or dominant viral population following the WT was being eliminated from infected livers during natural course of chronic HBV infection. The data strongly imply that WT or early HBV infection is frequently cleared at cccDNA level during chronic HBV infection. It is notable that such cccDNA clearance naturally occurs without intervention. This understanding is consistent with cccDNA clearance in adult patients with acute HBV infection in which HBV infection is naturally resolved, and no antiviral treatment is needed.

Available data also suggest that HBV WT is replaced with HBV MT in NAs-treated chronic HBV-infected patients as evidenced by emergence of drug resistant mutant infection [25, 82]. The drug mutant infection that may not bear drug resistant phenotypes was also frequently detected in new generation of NAs-treated patients. A recent report shows that approximately 50% of patients treated with tenofovir (TDF) who remained viremic, developed pol/RT mutant infection though none of patients showed the drug resistance phenotypes [83]. The frequency of mutant infection in this report may be still underestimated because only the pol/RT sequence was analyzed. The observation that drug-related mutants spread following elimination of WT during NAs treatment suggests frequent viral clearance at cccDNA level and new rounds of infection with mutants.


3. New strategy and therapeutics for treating HBV infection guided by the viral infection biology

We propose a new strategy for treating HBV infection. This strategy directly aims to establish HBsAg seroconversion as early as possible through administrating sufficient amount of specific neutralizing antibodies, which will constantly and completely neutralize extracellular viruses to block repeated rounds of infection. This new strategy represents a paradigm shift in treating HBV infection, which has been treated primarily by inhibiting viral replication.

3.1. Directly dealing with the huge pool of HBsAg in chronic HBV infection

As the evidence points out, chronic HBV infection is not a simple extension of the initial infection, but is established and maintained by new rounds of infection. A unique situation in HBV infection is that it produces a huge pool of subviral particles (HBsAg) that are 1000–10,000 fold higher than virions [84]. The HBsAg primarily depletes the limited amount of endogenous neutralizing antibodies and leaves virions unneutralized and infectious. Current treatment strategy and approved antivirals are not designed to deal with new rounds of infection, almost impossibly deliver HBsAg seroconversion, and this is why current treatment rarely cures chronic HBV infection. The key to curing chronic HBV infection is to establish HBsAg seroconversion and to interrupt the infection course as early as possible by providing and maintaining high level of HBV neutralizing antibodies until the amount of endogenous HBV neutralizing antibodies exceeds the amount of HBV particles or all infected cells cleared HBV.

Advantages of the new strategy:

  1. It directly immediately targets extracellular viruses and blocks the spread of infection;

  2. It facilitates permanent and complete viral clearance in the liver;

  3. It significantly reduces side effects of treating HBV infection. Unlike NAs and interferon that function intracellularly, the neutralizing antibody is to replenish a normal component of the immunity, which is relatively deficient in face of a huge pool of HBsAg, and it mainly functions extracellularly;

  4. Neutralizing efficacy does not depend on efficiency of viral replication in infected cells.


4. Conclusions

In this paper, we analyze the deficiencies of current HBV treatment strategy and antivirals and the reason why they cannot cure chronic HBV infection. We also review the viral infection biology to fresh our understanding of general phases and natural course of HBV infection. We conclude that a full-blown HBV infection is established and maintained through multiround infection. We propose a new strategy for treating HBV infection. The core of this new strategy is that we must achieve HBsAg seroconversion naturally or interventionally to effectively clear HBV infection. Under the proposed strategy, a main target of the treatment is extracellular viruses, and an effective therapeutics is specific neutralizing antibodies.


  1. 1. Hepatitis B [Internet] 2015. Available from:
  2. 2. Franco E, Bagnato B, Marino MG, Meleleo C, Serino L, Zaratti L. Hepatitis B: epidemiology and prevention in developing countries. World Journal of Hepatology. 2012;4(3):74–80. doi:10.4254/wjh.v4.i3.74. PubMed PMID: 22489259; PMCID: 3321493.
  3. 3. Beasley RP, Trepo C, Stevens CE, Szmuness W. The e antigen and vertical transmission of hepatitis B surface antigen. American Journal of Epidemiology. 1977;105(2):94–8. PubMed PMID: 835566.
  4. 4. Okada K, Kamiyama I, Inomata M, Imai M, Miyakawa Y. e antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants. The New England Journal of Medicine. 1976;294(14):746–9. doi:10.1056/NEJM197604012941402. PubMed PMID: 943694.
  5. 5. Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. The New England Journal of Medicine. 1975;292(15):771–4. doi:10.1056/NEJM197504102921503. PubMed PMID: 1113797.
  6. 6. Fattovich G, Brollo L, Giustina G, Noventa F, Pontisso P, Alberti A, Realdi G, Ruol A. Natural history and prognostic factors for chronic hepatitis type B. Gut. 1991;32(3):294–8. PubMed PMID: 2013423; PMCID: 1378837.
  7. 7. Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology. 1988;8(3):493–6. PubMed PMID: 3371868.
  8. 8. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer. 1988;61(10):1942–56. PubMed PMID: 2834034.
  9. 9. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, De Leo D, Degenhardt L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, Ezzati M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa YA, Haring D, Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Karthikeyan G, Kassebaum N, Keren A, Khoo JP, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz SE, Ohno SL, Mabweijano J, MacIntyre MF, Mallinger L, March L, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGrath J, Mensah GA, Merriman TR, Michaud C, Miller M, Miller TR, Mock C, Mocumbi AO, Mokdad AA, Moran A, Mulholland K, Nair MN, Naldi L, Narayan KM, Nasseri K, Norman P, O'Donnell M, Omer SB, Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian JD, Rivero AP, Padilla RP, Perez-Ruiz F, Perico N, Phillips D, Pierce K, Pope CA, 3rd, Porrini E, Pourmalek F, Raju M, Ranganathan D, Rehm JT, Rein DB, Remuzzi G, Rivara FP, Roberts T, De Leon FR, Rosenfeld LC, Rushton L, Sacco RL, Salomon JA, Sampson U, Sanman E, Schwebel DC, Segui-Gomez M, Shepard DS, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor JA, Thomas B, Tleyjeh IM, Towbin JA, Truelsen T, Undurraga EA, Venketasubramanian N, Vijayakumar L, Vos T, Wagner GR, Wang M, Wang W, Watt K, Weinstock MA, Weintraub R, Wilkinson JD, Woolf AD, Wulf S, Yeh PH, Yip P, Zabetian A, Zheng ZJ, Lopez AD, Murray CJ, AlMazroa MA, Memish ZA. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–128. doi:10.1016/S0140-6736(12)61728-0. PubMed PMID: 23245604.
  10. 10. Liao B, Wang Z, Lin S, Xu Y, Yi J, Xu M, Huang Z, Zhou Y, Zhang F, Hou J. Significant fibrosis is not rare in Chinese chronic hepatitis B patients with persistent normal ALT. PLoS One. 2013;8(10):e78672. doi:10.1371/journal.pone.0078672. PubMed PMID: 24205292; PMCID: 3808379.
  11. 11. Wang H, Xue L, Yan R, Zhou Y, Wang MS, Cheng MJ, Hai-Jun H. Comparison of histologic characteristics of Chinese chronic hepatitis B patients with persistently normal or mildly elevated ALT. PLoS One. 2013;8(11):e80585. doi:10.1371/journal.pone.0080585. PubMed PMID: 24260428; PMCID: 3832452.
  12. 12. Lai M, Hyatt BJ, Nasser I, Curry M, Afdhal NH. The clinical significance of persistently normal ALT in chronic hepatitis B infection. Journal of Hepatology. 2007;47(6):760–7. doi:10.1016/j.jhep.2007.07.022. PubMed PMID: 17928090.
  13. 13. Gui HL, Wang H, Yang YH, Wu YW, Zhou HJ, Guo SM, Lin LY, Wang L, Cai W, Chen R, Guo Q, Zhou XQ, Bao SS, Xie Q. Significant histopathology in Chinese chronic hepatitis B patients with persistently high-normal alanine aminotransferase. Journal of Viral Hepatitis. 2010;17(Suppl 1):44–50. doi:10.1111/j.1365-2893.2010.01270.x. PubMed PMID: 20586933.
  14. 14. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50(3):661–2. doi:10.1002/hep.23190. PubMed PMID: 19714720.
  15. 15. European Association For The Study Of The L. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. Journal of Hepatology. 2012;57(1):167–85. doi:10.1016/j.jhep.2012.02.010. PubMed PMID: 22436845.
  16. 16. Kwon H, Lok AS. Hepatitis B therapy. Nature Reviews Gastroenterology and Hepatology. 2011;8(5):275–84. doi:10.1038/nrgastro.2011.33. PubMed PMID: 21423260.
  17. 17. Trepo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet. 2014;384(9959):2053–63. doi:10.1016/S0140-6736(14)60220-8. PubMed PMID: 24954675.
  18. 18. Lok AS, Lai CL. Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology. Journal of Hepatology. 1990;10(1):29–34. PubMed PMID: 2307827.
  19. 19. Liaw YF, Tai DI, Chu CM, Pao CC, Chen TJ. Acute exacerbation in chronic type B hepatitis: comparison between HBeAg and antibody-positive patients. Hepatology. 1987;7(1):20–3. PubMed PMID: 2433203.
  20. 20. Sarin S, Kedarisetty C, Abbas Z, Amarapurkar D, Bihari C, Chan A, Chawla Y, Dokmeci AK, Garg H, Ghazinyan H, Hamid S, Kim D, Komolmit P, Lata S, Lee G, Lesmana L, Mahtab M, Maiwall R, Moreau R, Ning Q, Pamecha V, Payawal D, Rastogi A, Rahman S, Rela M, Saraya A, Samuel D, Saraswat V, Shah S, Shiha G, Sharma B, Sharma M, Sharma K, Butt A, Tan S, Vashishtha C, Wani Z, Yuen M-F, Yokosuka O. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014. Hepatology International. 2014;8(4):453–71.
  21. 21. Olson J, Kamath P. Acute-on-chronic liver failure: concept, natural history, and prognosis. Current Opinion in Critical Care. 2011;17(2):165–9.
  22. 22. Elbaz T, El-Kassas M, Esmat G. New era for management of chronic hepatitis C virus using direct antiviral agents: a review. Journal of Advanced Research. 2015;6(3):301–10. doi:10.1016/j.jare.2014.11.004. PubMed PMID: 26257927; PMCID: PMC4522579.
  23. 23. Mishra P, Murray J, Birnkrant D. Direct-acting antiviral drug approvals for treatment of chronic hepatitis C virus infection: scientific and regulatory approaches to clinical trial designs. Hepatology. 2015;62(4):1298–303. doi:10.1002/hep.27880. PubMed PMID: 25953139.
  24. 24. Lau DT, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, Kleiner DE, Schmid P, Condreay LD, Gauthier J, Kuhns MC, Liang TJ, Hoofnagle JH. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology. 2000;32(4 Pt 1):828–34. doi:10.1053/jhep.2000.17912. PubMed PMID: 11003630.
  25. 25. Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy. Hepatology. 2009;49(5 Suppl):S174–84. doi:10.1002/hep.22900. PubMed PMID: 19399794; PMCID: 2707848.
  26. 26. Luo J, Li X, Wu Y, Lin G, Pang Y, Zhang X, Ao Y, Du Z, Zhao Z, Chong Y. Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-naive chronic hepatitis B patients in real life. International Journal of Medical Sciences. 2013;10(4):427–33. doi:10.7150/ijms.5472. PubMed PMID: 23471472; PMCID: 3590603.
  27. 27. Pan CQ, Tong M, Kowdley KV, Hu KQ, Chang TT, Lai CL, Yoon SK, Lee SS, Cohen D, Tang H, Tsai N. High rates of viral suppression after long-term entecavir treatment of Asian patients with hepatitis B e antigen-positive chronic hepatitis B. Clinical Gastroenterology and Hepatology. 2012;10(9):1047–50 e1. doi:10.1016/j.cgh.2012.03.016. PubMed PMID: 22475742.
  28. 28. Lok AS, Trinh H, Carosi G, Akarca US, Gadano A, Habersetzer F, Sievert W, Wong D, Lovegren M, Cohen D, Llamoso C. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis B. Gastroenterology. 2012;143(3):619–28 e1. doi:10.1053/j.gastro.2012.05.037. PubMed PMID: 22643350.
  29. 29. Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Gurel S, Snow-Lampart A, Borroto-Esoda K, Mondou E, Anderson J, Sorbel J, Rousseau F. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology. 2011;140(1):132–43. doi:10.1053/j.gastro.2010.10.011. PubMed PMID: 20955704.
  30. 30. Zhu Y, Yamamoto T, Cullen J, Saputelli J, Aldrich CE, Miller DS, Litwin S, Furman PA, Jilbert AR, Mason WS. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. Journal of Virology. 2001;75(1):311–22. doi:10.1128/JVI.75.1.311-322.2001. PubMed PMID: 11119601; PMCID: 113925.
  31. 31. Wursthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P, Zollner B, Longerich T, Schirmacher P, Metzler F, Zankel M, Fischer C, Currie G, Brosgart C, Petersen J. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology. 2006;44(3):675–84. doi:10.1002/hep.21282. PubMed PMID: 16941693.
  32. 32. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, Trepo C, Marcellin P, Goodman Z, Delaney WE 4th, Xiong S, Brosgart CL, Chen SS, Gibbs CS, Zoulim F. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology. 2004;126(7):1750–8. PubMed PMID: 15188170.
  33. 33. Tseng TC, Kao JH. Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog. Journal of Gastroenterology. 2013;48(1):13–21. doi:10.1007/s00535-012-0668-y. PubMed PMID: 23090000; PMCID: 3698422.
  34. 34. Dahari H, Shudo E, Ribeiro RM, Perelson AS. Modeling complex decay profiles of hepatitis B virus during antiviral therapy. Hepatology. 2009;49(1):32–8. doi:10.1002/hep.22586. PubMed PMID: 19065674; PMCID: 3712859.
  35. 35. Perelson AS, Guedj J. Modelling hepatitis C therapy—predicting effects of treatment. Nature Reviews Gastroenterology and Hepatology. 2015;12(8):437–45. doi:10.1038/nrgastro.2015.97. PubMed PMID: 26122475; PMCID: PMC4692721.
  36. 36. Rivadeneira PS, Moog CH, Stan GB, Brunet C, Raffi F, Ferre V, Costanza V, Mhawej MJ, Biafore F, Ouattara DA, Ernst D, Fonteneau R, Xia X. Mathematical modeling of HIV dynamics after antiretroviral therapy initiation: a review. Bioresearch Open Access. 2014;3(5):233–41. doi:10.1089/biores.2014.0024. PubMed PMID: 25371860; PMCID: PMC4215334.
  37. 37. Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, Siegel D, Perron M, Bannister R, Hui HC, Larson N, Strickley R, Wells J, Stuthman KS, Van Tongeren SA, Garza NL, Donnelly G, Shurtleff AC, Retterer CJ, Gharaibeh D, Zamani R, Kenny T, Eaton BP, Grimes E, Welch LS, Gomba L, Wilhelmsen CL, Nichols DK, Nuss JE, Nagle ER, Kugelman JR, Palacios G, Doerffler E, Neville S, Carra E, Clarke MO, Zhang L, Lew W, Ross B, Wang Q, Chun K, Wolfe L, Babusis D, Park Y, Stray KM, Trancheva I, Feng JY, Barauskas O, Xu Y, Wong P, Braun MR, Flint M, McMullan LK, Chen SS, Fearns R, Swaminathan S, Mayers DL, Spiropoulou CF, Lee WA, Nichol ST, Cihlar T, Bavari S. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016;531(7594):381–5. doi:10.1038/nature17180. PubMed PMID: 26934220.
  38. 38. Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, Han KH, Chao YC, Lee SD, Harris M, Yang J, Colonno R, Brett-Smith H. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology. 2007;133(5):1437–44. doi:10.1053/j.gastro.2007.08.025. PubMed PMID: 17983800.
  39. 39. Bernuau J, Goudeau A, Poynard T, Dubois F, Lesage G, Yvonnet B, Degott C, Bezeaud A, Rueff B, Benhamou JP. Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology. 1986;6(4):648–51. PubMed PMID: 3732998.
  40. 40. Oren I, Hershow RC, Ben-Porath E, Krivoy N, Goldstein N, Rishpon S, Shouval D, Hadler SC, Alter MJ, Maynard JE, et al. A common-source outbreak of fulminant hepatitis B in a hospital. Annals of Internal Medicine. 1989;110(9):691–8. PubMed PMID: 2930106.
  41. 41. Tsang SW, Chan HL, Leung NW, Chau TN, Lai ST, Chan FK, Sung JJ. Lamivudine treatment for fulminant hepatic failure due to acute exacerbation of chronic hepatitis B infection. Alimentary Pharmacology and Therapeutics. 2001;15(11):1737–44. PubMed PMID: 11683687.
  42. 42. McMahon BJ, Alward WL, Hall DB, Heyward WL, Bender TR, Francis DP, Maynard JE. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. The Journal of Infectious Diseases. 1985;151(4):599–603. PubMed PMID: 3973412.
  43. 43. Parry MF, Brown AE, Dobbs LG, Gocke DJ, Neu HC. The epidemiology of hepatitis B infection in housestaff. Infection. 1978;6(5):204–6. PubMed PMID: 730389.
  44. 44. Sherlock S. The natural history of hepatitis B. Postgraduate Medical Journal. 1987;63(Suppl 2):7–11. PubMed PMID: 3317361.
  45. 45. Zhang YY, Summers J. Rapid production of neutralizing antibody leads to transient hepadnavirus infection. Journal of Virology. 2004;78(3):1195–201. PubMed PMID: 14722274; PMCID: 321410.
  46. 46. McMichael AJ, Rowland-Jones SL. Cellular immune responses to HIV. Nature. 2001;410(6831):980–7.
  47. 47. Bertoletti A, Gehring AJ. The immune response during hepatitis B virus infection. The Journal of General Virology. 2006;87(Pt 6):1439–49. doi:10.1099/vir.0.81920-0. PubMed PMID: 16690908.
  48. 48. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science. 1999;284(5415):825–9. PubMed PMID: 10221919.
  49. 49. Liaw YF, Sheen IS, Chen TJ, Chu CM, Pao CC. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology. 1991;13(4):627–31. PubMed PMID: 2010157.
  50. 50. Liu J, Yang HI, Lee MH, Lu SN, Jen CL, Wang LY, You SL, Iloeje UH, Chen CJ, Group R-HS. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology. 2010;139(2):474–82. doi:10.1053/j.gastro.2010.04.048. PubMed PMID: 20434450.
  51. 51. Barker LF, Murray R. Relationship of virus dose to incubation time of clinical hepatitis and time of appearance of hepatitis-associated antigen. The American Journal of the Medical Sciences. 1972;263(1):27–33. PubMed PMID: 5057849.
  52. 52. Liang TJ. Hepatitis B: the virus and disease. Hepatology. 2009;49(5 Suppl):S13–21. doi:10.1002/hep.22881. PubMed PMID: 19399811; PMCID: 2809016.
  53. 53. Chisari FV, Ferrari C. Hepatitis B virus immunopathology. Springer Seminars in Immunopathology. 1995;17(2–3):261–81. PubMed PMID: 8571172.
  54. 54. Chisari FV, Isogawa M, Wieland SF. Pathogenesis of hepatitis B virus infection. Pathologie-Biologie. 2010;58(4):258–66. doi:10.1016/j.patbio.2009.11.001. PubMed PMID: 20116937; PMCID: 2888709.
  55. 55. Zhang YY, Summers J. Enrichment of a precore-minus mutant of duck hepatitis B virus in experimental mixed infections. Journal of Virology. 1999;73(5):3616–22. Epub 1999/04/10. PubMed PMID: 10196253; PMCID: 104136.
  56. 56. Pult I, Abbott N, Zhang YY, Summers J. Frequency of spontaneous mutations in an avian hepadnavirus infection. Journal of Virology. 2001;75(20):9623–32. doi:10.1128/JVI.75.20.9623-9632.2001. PubMed PMID: 11559794; PMCID: 114533.
  57. 57. Brunetto MR, Giarin MM, Oliveri F, Chiaberge E, Baldi M, Alfarano A, Serra A, Saracco G, Verme G, Will H, et al. Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. Proceedings of the National Academy of Sciences USA. 1991;88(10):4186–90. Epub 1991/05/15. PubMed PMID: 2034663; PMCID: 51623.
  58. 58. Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, Thomas HC. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet. 1989;2(8663):588–91. PubMed PMID: 2570285.
  59. 59. Karasawa T, Shirasawa T, Okawa Y, Kuramoto A, Shimada N, Aizawa Y, Zeniya M, Toda G. Association between frequency of amino acid changes in core region of hepatitis B virus (HBV) and the presence of precore mutation in Japanese HBV carriers. Journal of Gastroenterology. 1997;32(5):611–22. Epub 1997/11/14. PubMed PMID: 9349986.
  60. 60. Lin CL, Liao LY, Liu CJ, Chen PJ, Lai MY, Kao JH, Chen DS. Hepatitis B genotypes and precore/basal core promoter mutants in HBeAg-negative chronic hepatitis B. Journal of Gastroenterology. 2002;37(4):283–7. Epub 2002/05/08. PubMed PMID: 11993512.
  61. 61. Funk ML, Rosenberg DM, Lok AS. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. Journal of Viral Hepatitis. 2002;9(1):52–61. Epub 2002/02/20. PubMed PMID: 11851903.
  62. 62. Okamoto H, Tsuda F, Akahane Y, Sugai Y, Yoshiba M, Moriyama K, Tanaka T, Miyakawa Y, Mayumi M. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. Journal of Virology. 1994;68(12):8102–10. Epub 1994/12/01. PubMed PMID: 7966600; PMCID: 237274.
  63. 63. Omata M, Ehata T, Yokosuka O, Hosoda K, Ohto M. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. The New England Journal of Medicine. 1991;324(24):1699–704. Epub 1991/06/13. doi:10.1056/NEJM199106133242404. PubMed PMID: 2034246.
  64. 64. Tur-Kaspa R, Klein A, Aharonson S. Hepatitis B virus precore mutants are identical in carriers from various ethnic origins and are associated with a range of liver disease severity. Hepatology. 1992;16(6):1338–42. PubMed PMID: 1446889.
  65. 65. Shiraki K, Hamada M, Sugimoto K, Ito T, Yamanaka T, Wagayama H, Shimizu A, Makino Y, Takase K, Nakano T, Tameda Y. Detection of precore-mutant hepatitis B virus genome in patients with acute and fulminant hepatitis using mutation site-specific assay (MSSA). Hepatogastroenterology. 2002;49(47):1352–6. Epub 2002/09/21. PubMed PMID: 12239941.
  66. 66. Chu CM, Yeh CT, Chiu CT, Sheen IS, Liaw YF. Precore mutant of hepatitis B virus prevails in acute and chronic infections in an area in which hepatitis B is endemic. Journal of Clinical Microbiology. 1996;34(7):1815–8. Epub 1996/07/01. PubMed PMID: 8784599; PMCID: 229124.
  67. 67. Santantonio T, Jung MC, Miska S, Pastore G, Pape GR, Will H. Prevalence and type of pre-C HBV mutants in anti-HBe positive carriers with chronic liver disease in a highly endemic area. Virology. 1991;183(2):840–4. PubMed PMID: 1853582.
  68. 68. Santantonio T, Jung MC, Miska S, Pastore G, Pape GR, Will H. High prevalence and heterogeneity of HBV preC mutants in anti-HBe-positive carriers with chronic liver disease in southern Italy. Journal of Hepatology. 1991;13(Suppl 4):S78–81. Epub 1991/01/01. PubMed PMID: 1822518.
  69. 69. Manzin A, Paolucci S, Lampertico P, Menzo S, Rumi MG, Colombo M, Clementi M. Direct detection of HBV preC mutants in heterogeneous viral populations by a modified DNA sequencing method. Research in Virology. 1993;144(4):303–6. Epub 1993/07/01. PubMed PMID: 8210713.
  70. 70. Chan HL, Leung NW, Hussain M, Wong ML, Lok AS. Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong. Hepatology. 2000;31(3):763–8. doi:10.1002/hep.510310330. PubMed PMID: 10706570.
  71. 71. Brunetto MR, Stemler M, Bonino F, Schodel F, Oliveri F, Rizzetto M, Verme G, Will H. A new hepatitis B virus strain in patients with severe anti-HBe positive chronic hepatitis B. Journal of Hepatology. 1990;10(2):258–61. Epub 1990/03/01. PubMed PMID: 2332598.
  72. 72. Okamoto H, Yotsumoto S, Akahane Y, Yamanaka T, Miyazaki Y, Sugai Y, Tsuda F, Tanaka T, Miyakawa Y, Mayumi M. Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen. Journal of Virology. 1990;64(3):1298–303. Epub 1990/03/01. PubMed PMID: 2304145; PMCID: 249247.
  73. 73. Raimondo G, Schneider R, Stemler M, Smedile V, Rodino G, Will H. A new hepatitis B virus variant in a chronic carrier with multiple episodes of viral reactivation and acute hepatitis. Virology. 1990;179(1):64–8. PubMed PMID: 2219740.
  74. 74. Tong SP, Li JS, Vitvitski L, Trepo C. Active hepatitis B virus replication in the presence of anti-HBe is associated with viral variants containing an inactive pre-C region. Virology. 1990;176(2):596–603. PubMed PMID: 2345966.
  75. 75. Li J, Tong S, Vitvitski L, Zoulim F, Trepo C. Rapid detection and further characterization of infection with hepatitis B virus variants containing a stop codon in the distal pre-C region. The Journal of General Virology. 1990;71 (Pt 9):1993–8. Epub 1990/09/01. PubMed PMID: 2212990.
  76. 76. Raimondo G, Stemler M, Schneider R, Wildner G, Squadrito G, Will H. Latency and reactivation of a precore mutant hepatitis B virus in a chronically infected patient. Journal of Hepatology. 1990;11(3):374–80. Epub 1990/11/01. PubMed PMID: 2290029.
  77. 77. Lindh M, Furuta Y, Vahlne A, Norkrans G, Horal P. Emergence of precore TAG mutation during hepatitis B e seroconversion and its dependence on pregenomic base pairing between nucleotides 1858 of 1896. Journal of Infectious Diseases. 1995;172(5):1343–7. Epub 1995/11/01. PubMed PMID: 7594674.
  78. 78. Brunetto MR, Giarin M, Saracco G, Oliveri F, Calvo P, Capra G, Randone A, Abate ML, Manzini P, Capalbo M, et al. Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B. Gastroenterology. 1993;105(3):845–50. PubMed PMID: 7689519.
  79. 79. Lok AS, Akarca U, Greene S. Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal. Proceedings of the National Academy of Sciences United States of America. 1994;91(9):4077–81. Epub 1994/04/26. PubMed PMID: 8171038; PMCID: 43726.
  80. 80. Locarnini S, Zoulim F. Molecular genetics of HBV infection. Antiviral Therapy. 2010;15(Suppl 3):3–14. Epub 2010/11/10. doi:10.3851/IMP1619. PubMed PMID: 21041899.
  81. 81. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology. 2009;137(5):1593–608 e1–2. doi:10.1053/j.gastro.2009.08.063. PubMed PMID: 19737565.
  82. 82. Locarnini S, Bowden S. Drug resistance in antiviral therapy. Clinics in Liver Disease. 2010;14(3):439–59. Epub 2010/07/20. doi:10.1016/j.cld.2010.05.004. PubMed PMID: 20638024.
  83. 83. Kitrinos KM, Corsa A, Liu Y, Flaherty J, Snow-Lampart A, Marcellin P, Borroto-Esoda K, Miller MD. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology. 2014;59(2):434–42.
  84. 84. Ganem D, Prince AM. Hepatitis B virus infection--natural history and clinical consequences. The New England Journal of Medicine. 2004;350(11):1118–29. doi:10.1056/NEJMra031087. PubMed PMID: 15014185.

Written By

Yong-Yuan Zhang

Submitted: 25 April 2016 Reviewed: 29 September 2016 Published: 08 March 2017